News | February 23, 2022
GSK introduces Haleon to the world
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New inhalers would have near-zero Global Warming Potential propellant
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Subscribe To Our Newsletter & Stay Updated
